Dual renin-angiotensin system blockade at optimal doses for proteinuria  by Laverman, Gozewijn D. et al.
Kidney International, Vol. 62 (2002), pp. 1020–1025
Dual renin-angiotensin system blockade at optimal doses
for proteinuria
GOZEWIJN D. LAVERMAN, GERJAN NAVIS, ROBERT H. HENNING, PAUL E. DE JONG, and
DICK DE ZEEUW
Division of Nephrology, Department of Medicine, and Department of Clinical Pharmacology, Groningen University
Institute for Drug Exploration (GUIDE), University of Groningen, Groningen, The Netherlands
Dual renin-angiotensin system blockade at optimal doses for enzyme inhibitors (ACEi) has been demonstrated both
proteinuria. in diabetic [1] and non-diabetic renal disease [2]. The
Background. The antiproteinuric effect of combining the more recently introduced angiotensin II antagonistsangiotensin-converting enzyme (ACE) inhibitor lisinopril and
(Ang IIA) also are renoprotective, at least in type-2the angiotensin II (Ang II) antagonist losartan was compared
to that of the optimal antiproteinuric doses of monotherapy. diabetic nephropathy [3, 4].
Methods. To this purpose, lisinopril and losartan were stud- Several lines of evidence indicate that the renoprotec-
ied in 9 nondiabetic renal patients with median proteinuria tive efficacy of RAS-blocking agents is related to their4.5 g/day (95% CI, 3.5, 6.4), creatinine clearance of 80 mL/
antiproteinuric properties. The antiproteinuric responsemin (95% CI, 66, 96), and mean arterial pressure (MAP) of
to intervention is the strongest predictor of long-term102 mm Hg (95% CI, 93, 112). First, in two protocols with six-
week treatment periods per dose, the optimal antiproteinuric renoprotective efficacy [5–7]. Evidence from large clini-
dose of each drug was established in each patient. Losartan cal trials is now available showing that residual protein-and lisinopril were used in randomized order, each preceded
uria during treatment is an independent risk factor forby a baseline period without medication. The doses of losartan
progression of renal disease. Thus, reduction of protein-(mg/day) were 50, 100, 150, and again 50. The lisinopril doses
were 10, 20, 40, and again 10. After the second protocol, pa- uria should be an independent therapeutic target [8].
tients were treated with a combination, using the optimal anti- Consequently, the focus of renoprotective interventionproteinuric doses established for the individual drugs.
has shifted toward optimal reduction of proteinuria, inResults. The antiproteinuric response by losartan was opti-
addition to control of blood pressure [9, 10].mal at 100 mg (46%; 95% CI, 60, 24%), being larger
than at the 50 mg dose (27%; 95% CI,42,4%, P 0.05), Treatment schedules should be developed that afford
but not different from the 150 mg dose (46%; 95% CI, 58; optimal reduction of proteinuria in addition to blood
20%). Proteinuria decreased further at each up-titration step
pressure control. Considering the consistent antiprotein-of lisinopril to75% (95% CI,85,43%) at the 40 mg dose.
uric effects of RAS-blocking agents, the first step shouldCombination therapy reduced proteinuria more effectively
(85%; 95% CI, 96, 58) than monotherapy with losartan, be to establish the optimal treatment schedule for reduc-
and to a lesser extent than with lisinopril. Optimal blood pres- tion of proteinuria using these drugs.
sure responses were obtained at similar doses.
First, dosing is important. The recommended doses ofConclusions. Dose-titration with a renin-angiotensin system
ACEi and Ang IIA are derived from hypertension trials,blocker, followed by add-on therapy is highly effective in order
to reduce proteinuria. The safety of this regimen needs to be but the dose-response for the antiproteinuric effect may
addressed in future studies. not be similar to the dose-response for blood pressure.
For example, animal experiments showed that doses of
ACEi and Ang IIA higher than needed for optimal bloodTreatment with agents interfering in the renin-angioten-
pressure control, provided additional renoprotection [11].sin system (RAS) retards the progressive course of chronic
Unfortunately, dose-finding studies for proteinuria inrenal disease. The efficacy of angiotensin-converting
humans are scarce [12, 13]. Moreover, it is well recog-
nized that the dose needed to reach a blood pressure tar-
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get can be different between patients, and it would benondiabetic renal disease, dose-response, add-on therapy, progressive
renal disease. relevant to see whether this also applies to reduction of
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via non-ACE pathways [14], monotherapy with an ACEi doses were 10 mg, 20 mg, 40 mg and 10 mg. Immediately
could result in suboptimal blockade of the RAS, even after completing the second protocol, patients were treated
at the maximally effective dose. On the other hand, for six weeks with the combination of both drugs. To
blocking the angiotensin II type 1 (AT1) receptor by that purpose, each drug was administered at the dose
monotherapy with an Ang IIA results in a compensatory that had rendered optimal antiproteinuric efficacy in that
rise in renin, and consequently Ang II, with so far un- individual patient.
known consequences.
Thus, in order to improve antiproteinuric therapy both Clinical and laboratory procedures
optimization of the dose and dual blockade of the RAS Blood pressure was measured at every visit under
may be fruitful. Several studies have investigated dual
similar conditions, at trough at one minute intervals byRAS blockade in nondiabetic [15, 16], diabetic [17] or
a Dinamap, with the patient in supine position. Aftermixed renal patients [18], with promising, but not uni-
fifteen minutes of measurements, the mean of the lastform results.
four readings was used for further analysis. Mean arterialNone of these studies tested whether the applied doses
pressure (MAP) was calculated as the sum of one-thirdof both drugs were on the top of the dose-response for
systolic and two-thirds of the diastolic blood pressure.proteinuria. Consequently, an observed added effect of
Urinary protein was determined using the pyrogallol red-the combination also might have been obtained by mo-
molybdate method. At the end of each period, patientsnotherapy at a higher dose. Therefore, in the present
collected urine for two consecutive days. Daytime andstudy, we first aimed to establish the optimal antiprotein-
nighttime samples were collected separately by the pa-uric dose for monotherapy with the ACEi lisinopril and
tients. The general results on proteinuria were obtainedthe Ang IIA losartan for individual renal patients with
nondiabetic proteinuria. Subsequently, patients were from the 24 hour amounts. In addition, the relative day-
treated with a combination of the optimal dose of both and nighttime efficacy of proteinuria reduction was com-
drugs to test whether this results in a stronger reduction pared between both drugs. To this end, day/night ratios
of proteinuria than either drug alone. (in duplicate, corrected for creatinine) were calculated
at baseline and at each dose of both drugs. Serum and
urinary electrolytes, uric acid and creatinine were deter-METHODS
mined using an automated multi-analyzer (SMA-C;Patients and protocol
Technicon, Tarrytown, NY, USA).
Patients were selected from our renal outpatient de-
partment. All patients gave informed consent and, after Data analysis
at least six weeks without antihypertensive medication,
Results are expressed as median and 95% confidencefulfilled the following inclusion criteria: stable protein-
intervals (95% CI). Blood pressure is expressed as meanuria 2 g/day and diastolic blood pressure between 80
arterial pressure. Proteinuria at the end of each periodand 110 mm Hg, a creatinine clearance 30 mL/min/
is represented as residual proteinuria and as percentage1.73 m2 and age between 18 and 70 years. Patients with
change from baseline (mean of two baseline values). Forcardiovascular disorders or diabetes mellitus were ex-
each patient, the lowest level of proteinuria, obtainedcluded, as well as frequent users of non-steroidal anti-
during monotherapy with losartan and lisinopril was es-inflammatory drugs (NSAIDs; 2 doses/week).
This outpatient study was performed open-label and tablished. Then, the Wilcoxon Signed Ranks Test was
the patients were instructed to take the study medication used to test whether these values differed from combined
once daily, in the morning, except on the study days: on therapy. Differences were considered significant if the
those days the study drug was taken after the hospital P value was0.05. Previously, we calculated that a sam-
visit, so blood pressure was measured at trough. During ple size of N 10 is needed to detect changes in protein-
the period of combined treatment, lisinopril was taken uria of 0.5 g/day with expected standard deviation of
in the evening and losartan was taken in the morning. 0.5 g/day with a desired power of 0.8 and alpha 0.05 [13].
Patients were instructed to adhere to a dietary sodium-
restriction of 5 to 7 g/day.
The study consisted of two titration protocols with the RESULTS
respective monotherapies in randomized order. Before
Patient characteristicsboth titration schedules, there was a baseline period
Ten consecutive patients were included, all of whomwithout medication. All treatment periods, including the
were middle-aged Caucasians. One patient was not abletwo baseline periods, lasted six weeks. The consecutive
to maintain scheduled visits and was excluded. The ninedaily doses in the losartan protocol were 50 mg, 100 mg,
150 mg and 50 mg. In the lisinopril protocol, the daily patients who completed the entire protocol had mildly
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Table 1. Patient characteristics (without medication,
median and 95% CI or number)
Male/female 6/3
Age years 51 (44; 55)
Creatinine clearance mL/min 80 (66; 96)
Supine blood pressure mm Hg
Systolic 137 (130; 152)
Diastolic 80 (73; 89)
Diagnosis FSGS (4), MGP (3), IgA (1), NCBx (1)
Previous medication ena (6), ena/hct (1), lis/hct (1), los (1)
Abbreviations are: FSGS, focal and segmental glomerulosclerosis; MGP,
membranous glomerulopathy; IgA, IgA nephropathy; NCBx, non-conclusive
biopsy; ena, enalapril; hct, hydrochlorothiazide; lis, lisinopril; los, losartan.
to moderately impaired renal function and were normo-
Fig. 1. Response of proteinuria according to the dose of losartan (A)tensive without medication (Table 1).
or lisinopril (B) in nine non-diabetic renal patients. Data are median,
95% CI. Note that the response to combined therapy () is the same
Proteinuria during treatment with losartan, lisinopril value in both panels. Responses are expressed as % change from base-
line. The baseline value was calculated as the mean of two six-weekand the combination
periods without medication. All doses resulted in a significant change
Baseline proteinuria was 4.5 g/day (95% CI, 3.5, 6.4). from baseline.
In the losartan protocol, maximal antiproteinuric efficacy
was obtained with the 100 mg dose (Fig. 1A), corre-
sponding to a residual proteinuria of 2.8 g/day (95% CI, treatment periods, respectively. The day/night ratios with
1.5, 4.6). Increasing the dose to 150 mg/d did not further lisinopril were similar, 1.4 (1.1; 2.1), 1.4 (1.0; 2.5), 1.5
reduce proteinuria (2.6 g/day; 95% CI, 1.5, 4.9). After (0.8; 2.2) and 1.4 (0.9; 2.2). After combined treatment, the
down-titration of losartan from 150 to 50 mg/day, protein- ratio was 1.5 (1.1; 2.3). Thus, the relative antiproteinuric
uria increased to 3.3 g/day (95% CI, 1.9, 4.8), which was efficacy during day and night was similar for both drugs
not different from the first 50 mg dose period (3.3 g/day; individually and for the combination.
95% CI, 2.1, 5.8), demonstrating stability of the protein-
uric condition during the time course of the protocol. Blood pressure during treatment with losartan,
Dose-titration with lisinopril revealed a different pat- lisinopril and combination therapy
tern (Fig. 1B), as each up-titration step resulted in a fur- Baseline mean arterial blood pressure was 102 mm Hg
ther reduction of proteinuria. Residual proteinuria after (95% CI, 93, 112). Blood pressure was lowered by all doses
lisinopril 40 mg/day was 1.4 g/day (95% CI, 0.5, 3.2), which of losartan and lisinopril (Fig. 2). The differences in
was significantly lower, not only than residual proteinuria MAP after losartan 50 mg/day (92 mm Hg, 95% CI, 89,
after lisinopril 20 mg/day (2.2 g/day; 95% CI, 1.5, 3.6) 96), losartan 100 mg/day (87 mm Hg, 95% CI, 83, 95)
and lisinopril 10 mg/day (3.3 g/day; 95% CI, 1.7, 4.8), and losartan 150 mg/day (89 mm Hg, 95% CI, 79, 97)
but also than losartan 150 mg/day. After down-titration were not statistically different. During dose-titration with
of lisinopril from 40 to 10 mg/day, proteinuria remained lisinopril, the lowest MAP was achieved with the 40 mg
significantly lower (2.0 g/day; 95% CI, 1.1, 3.5) than after dose (77 mm Hg; 95% CI, 74, 92). This was significantly
the first treatment period with lisinopril 10 mg/day. lower than MAP after lisinopril 10 mg/day (90 mm Hg,
After completing the second titration protocol, patients 95% CI, 81, 96), but non-significantly different from lisi-
were simultaneously treated with both drugs at their nopril 20 mg/day (82 mm Hg, 95% CI, 80, 94). Combina-
individual optimal antiproteinuric dose. Combined ther- tion therapy lowered MAP to a level lower than the op-
apy consisted of losartan 150 mg and lisinopril 40 mg in timal dose of losartan, but not different from the optimal
three cases, losartan 100 mg and lisinopril 40 mg in two dose of lisinopril (Table 2).
cases, losartan 100 mg and lisinopril 20 mg in two cases,
and losartan 50 mg and lisinopril 40 mg in two cases. Com- Adverse events
bined treatment with lisinopril and losartan resulted in None of the patients dropped out of the study because
an antiproteinuric response that was significantly stronger of adverse drug effects. Nevertheless there were a few
than monotherapy with losartan or lisinopril (Fig. 1 and cases of dizziness and hyperkalemia (Table 2).
Table 2).
The day/night ratio of proteinuria at baseline was 1.5
DISCUSSION(1.1; 1.6). This ratio did not change during therapy. The
ratios obtained with losartan were 1.4 (1.2; 2.0), 1.3 (1.0; The present study first showed that agents interfering
in the RAS cause a dose-dependent decrease of protein-2.0), 1.6 (1.3; 2.1) and 1.5 (1.3; 2.2) for the consecutive
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Table 2. Median (95% CI) of parameters at baseline, after the optimal dose of monotherapy (losartan, lisinopril)
and after combination therapy
Baselinea Losartan Lisinopril Lis  Los
Uprot g/day 4.5 (3.5; 6.4) 2.2 (1.2; 4.8)b 1.4 (0.5; 2.9)bc 1.0 (0.0; 2.6)bcd
MAP mm Hg 102 (93; 112) 88 (81; 98)b 77 (74; 90)bc 77 (73; 85)bc
CCr mL/min 80 (66; 96) 73 (59; 89) 72 (52; 92) 66 (51; 80)b
BW kg 76 (69; 85) 78 (70; 87) 74 (70; 84) 75 (70; 84)
UNa mmol/day 121 (75; 182) 113 (75; 143) 109 (72; 139) 101 (69; 138)
SUA mmol/L 0.43 (0.39; 0.47) 0.43 (0.40; 0.46) 0.49 (0.44; 0.53) 0.46 (0.41; 0.51)
Schol mmol/L 6.0 (5.5; 6.6) 6.0 (5.0; 7.0) 5.8 (5.3; 6.3) 5.5 (5.1; 5.9)
SK 5.5 N 0 1 2 2
Dizziness N 0 1 1 2
Abbreviations are: Uprot, proteinuria; MAP, mean arterial pressure; CCr, creatinine clearance; BW, body weight; UNa, urinary sodium excretion, SUA, serum uric
acid, Schol, serum cholesterol, SK, serum potassium.
a Mean of two baseline periods
b P  0.05 vs. baseline
c P  0.05 vs. optimal dose of losartan
d P  0.05 vs. optimal dose of lisinopril
certain drug are different because of patient factors such
as the genetic background (for example, polymorphisms
of RAS components) or type and severity of the renal
disease. However, because of its small size, the present
study is not well suited to analyze determinants of the
response variability.
Increasing the dose of lisinopril resulted in a progres-
sive decline of proteinuria at each up-titration step, sug-
gesting that 40 mg/day was not on the top of the dose-
response. Dosing beyond 40 mg/day may even be more
effective than the obtained 75% reduction. However,
the blood pressure levels obtained were already very low
and the tolerability of higher doses is a concern, espe-
cially in normotensive patients. The maximum antipro-
Fig. 2. Response of mean arterial pressure (MAP) to the dose of losar- teinuric response to losartan, which was already obtained
tan (A) or lisinopril (B) in nine non-diabetic renal patients. Data are at the 100 mg dose, was less effective than to lisinopril.median, 95% CI. Note that the response to combined therapy () is
Findings for blood pressure were similar. Since this studythe same value in both panels. Responses are expressed as % change
from baseline. Baseline value was calculated as the mean of two six- was not designed to compare both drugs, additional stud-
week periods without medication. ies are necessary to put this finding into the proper per-
spective. For a complete titration schedule, for instance,
a 200 mg dose of losartan should have been used, that
is, doubling of the dose at each up-titration step analoguria. Second, the combination of the ACEi lisinopril and
to the lisinopril schedule. However, unfortunately nothe Ang IIA losartan at their maximally effective dose
toxicity data on high doses of losartan were available tocaused an additional reduction in proteinuria and blood
justify such a study design.pressure. To our knowledge, this is the first study showing
At the group level, lisinopril lowered both proteinuriaan added effect of dual RAS blockade taking into account
and blood pressure somewhat more effectively than lo-the dose-response of the respective monotherapies.
sartan. This was not the result of a difference in durationOur study was designed to establish the optimal strat-
of action, given our results on day- and nighttime protein-egy for reduction of proteinuria with RAS blockers. To
uria. It may be that the differences in antiproteinuricthat purpose, we first investigated the effect of increasing
efficacy are due to different blood pressure control. How-the dose of the ACEi lisinopril and the Ang IIA losartan.
ever, no clear-cut correlation between both parametersImportantly, the optimal antiproteinuric dose differed
was found, which is consistent with the literature thatper individual, implicating that the responsiveness to
RAS blocking agents have antiproteinuric effects inde-antiproteinuric intervention displays interindividual dif-
pendent of the blood pressure response [21–23]. To dateferences. The importance of individual factors in drug
the mechanism of the antiproteinuric action is incom-response is increasingly recognized [19, 20]. Several fac-
pletely understood. Whereas a lower systemic blood pres-tors could be involved in the differences. For instance,
it could be speculated that the pharmacokinetics of a sure contributes to the reduction in proteinuria, blood
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pressure and proteinuria also could be independent re- patients with IgA nephropathy reported on the antipro-
teinuric effect of increasing doses of lisinopril [12]. Pro-flections of the therapeutic efficacy of lisinopril.
This study tested the combined effects of an ACEi teinuria progressively decreased from 1.8 g/day to 0.6 g/
day with increasing the lisinopril dose up to 20 mg/day.and an Ang IIA, taking into consideration the optimal
antiproteinuric dose of the single agents. The combina- Although proteinuria did not fully recover between the
treatment periods, the antiproteinuric response to lisino-tion had a considerably stronger antiproteinuric and anti-
hypertensive effect than monotherapy losartan. In com- pril seemed dose-dependent in the lower dosing-range.
Our current study shows that further increasing the doseparison to the highest tested dose of the ACEi, the
combination also provided an antiproteinuric response of lisinopril to 40 mg/day results in a considerable addi-
tional reduction. With respect to Ang IIA, two reportsthat was somewhat stronger. However, we cannot ex-
clude the possibility that increasing the dose of lisinopril indicated that the optimal dose of losartan is 100 mg/day
in both diabetic (abstract; Andersen et al, J Am Socwould have rendered a similar result, and it cannot be
established from our data whether addition of Ang IIA Nephrol 11:112A, 2000) and non-diabetic renal patients
[13]. On the other hand, the use of supramaximal doses ofto ACEi dosed at its maximally effective dose would
have resulted in an added effect. We recently found that the Ang IIA candesartan appeared promising in another
study [28]. Thus, the dosing-issue, especially with respectaddition of Ang IIA to ACEi at the well-established
top of its dose-response failed to enhance the therapy- to potential differences between Ang II antagonists, needs
to be further elucidated in future research.response in experimental nephrosis [24].
Importantly, the doses were increased in six-week Increasing the dose of the individual drugs prior to
the combination treatment effectively improved the anti-treatment periods without washout periods between the
treatment periods. It has been demonstrated previously proteinuric response. Some other studies have applied
a dual RAS blockade from a somewhat different per-that the antiproteinuric response stabilizes after approxi-
mately four weeks [25]. This protocol was deliberately spective. For example, in patients with IgA nephropathy,
there was additional antiproteinuric effect of adding lo-chosen because, rather than testing the effect of a dose
per se, the approach of up-titration itself is important to sartan to a deliberately chosen sub-hypotensive dose of
an ACEi [15], and the combination of relatively lowobtain the optimal reduction of proteinuria. Thus, although
less relevant for clinical practice, the possibility of carry- doses of losartan and enalapril were more effective than
a somewhat higher dose of either monotherapy [16]. Thisover should be considered. In case of losartan, carry-
over effects seem absent, as blood pressure and protein- is important, since combining low doses may have the
benefit of fewer side effects. A well-designed study in pri-uria levels in the first dosing period were similar to those
measured after down-titration during the last period. marily African American diabetic patients found no ad-
ditional antiproteinuric effect by adding losartan 50 mgWith lisinopril, blood pressure completely recovered dur-
ing the down-titration period, whereas recovery of pro- to lisinopril 40 mg [18]. These were therapy-resistant pa-
tients with uncontrolled blood pressure despite the useteinuria amounted to about two-thirds. However, a carry-
over effect with lisinopril is unlikely to confound the of several antihypertensive drugs, suggesting that differ-
ences between the studied populations exist, such as lessresults on proteinuria during combined treatment. Al-
though the down-titration period did not result in a com- efficacy of the RAS blockade in African Americans [29],
which could be important determinants of the therapeu-plete recovery of proteinuria to baseline values during the
study period, levels dropped to those observed at 20 mg tic response. Finally, whether an additional reduction of
proteinuria is found in add-on schemes also could belisinopril. As all patients received at least 20 mg lisinopril
during the combination treatment period, the influence determined by the order of application of the drugs, as
was indicated by our own findings.of suboptimal recovery of proteinuria seems limited.
No other renoprotective or antihypertensive drugs were None of our patients dropped out of the study because
of side effects. Nevertheless, the small size of the presentused. It is well established that the antiproteinuric and
antihypertensive effect of both ACEi and Ang IIA is im- study does not allow conclusions on safety and/or tolera-
bility. The risk for hypotension or hyperkalemia duringproved with concomitant diuretic treatment of sodium
restriction [26, 27]. It would therefore be worthwhile to combined ACEi and Ang IIA at high doses especially
needs to be evaluated.test whether further optimization of the antiproteinuric
response could be obtained by combining a dual RAS In summary, RAS blockers have a dose-response for
proteinuria and the combination of the ACEi lisinoprilblockade with a diuretic and/or more rigid sodium re-
striction. and the Ang IIA losartan was clearly more effective in
reducing proteinuria than the maximally effective doseAlthough the importance of titration according to the
antiproteinuric response has been recognized [9, 10], dose- of losartan. Dual blockade was also somewhat more ef-
fective than lisinopril, but further studies should be con-response studies with ACE inhibitors or Ang II antago-
nists are scarce. To our knowledge, only one study in ducted to establish whether an additional reduction of
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of lisinopril on proteinuria of normotensive patients with IgA ne-proteinuria could safely be obtained by supramaximal
phropathy and normal renal function. Int J Clin Pharmacol Res
doses of lisinopril. In conclusion, dose-titration with a 14:35–43, 1994
13. Laverman GD, Henning RH, De Jong PE, et al: Optimal antipro-RAS blocker followed by add-on therapy is a highly ef-
teinuric dose of losartan in nondiabetic patients with nephroticfective approach to reduce proteinuria. The safety of
range proteinuria. Am J Kidney Dis 38:1381–1384, 2001
combined therapy at high doses needs to be addressed 14. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin
II generation in intact human tissue: Evidence from comparativein future studies.
pharmacological interruption of the renin system. Hypertension
32:387–392, 1998
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